The OASIS Consortium: integrating multi-omics technologies to transform chemical safety assessment.

Next Generation Risk Assessment (NGRA) aims to improve safety testing of pharmaceuticals, agrochemicals, and industrial chemicals. NGRA employs new approach methodologies, such as novel in vitro assays coupled with exposure modeling, to minimize the use of animal models, which can fail to predict specific biological effects in humans. The strategy of the 'Omics for Assessing Signatures for Integrated Safety (OASIS) Consortium combines multi-omics technologies (including transcriptomics, proteomics, and Cell Painting [high-content imaging]) and multiple cell model systems (ranging from simple cell cultures to complex organotypic models). By integrating these approaches with internal exposure estimates, the consortium aims to improve the translation between in vitro and in vivo test systems, ultimately enhancing the relevance of safety assessment to human biology. OASIS's integrated approach aims to better translate the biological effects across different chemical and biological spaces, starting with the liver as a use case. By using compounds with well-characterized in vivo and in vitro nonclinical safety and toxicology data related to adverse organ-specific effects in rats and humans, OASIS aims to create novel integrated methods that improve safety assessment while reducing animal use. Ideally, these efforts will contribute to regulatory science across sectors and support the adoption of more predictive, efficient, and cost-effective toxicological models.